Quarterly report [Sections 13 or 15(d)]

Segment Information (Details)

v3.26.1
Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Feb. 28, 2026
Nov. 30, 2025
Aug. 31, 2025
Feb. 28, 2025
Nov. 30, 2024
Aug. 31, 2024
Feb. 28, 2026
Feb. 28, 2025
Operating expenses:                
Legal settlement loss             $ 16,587  
Total operating expenses $ 6,303     $ 4,003     32,936 $ (14,727)
Operating (loss) gain (6,303)     (4,003)     (32,936) 14,727
Interest income 15     173     166 441
Interest on convertible notes (614)     (1,143)     (1,934) (3,469)
Amortization of discount on convertible notes       (110)       (348)
Standby equity purchase agreement commitment fee             $ (325)  
Number of reportable segments not disclosed             true  
Issuance costs for private placement of shares and warrants through placement agent (Note 5) (1,628)           $ (1,628)  
Legal settlement revaluation 3,842           3,842  
Loss on induced conversion               (1,180)
Finance charges (2)     (2)     (22) (25)
Gain on restructuring of payables       327       407
Loss on derivatives               (852)
Net (loss) income (4,690) $ (22,607) $ (5,540) (4,758) $ (4,768) $ 19,227 (32,837) 9,701
Share based compensation recognized in general and administrative expense 100     100     300 600
Share based compensation recognized in research and development expense 400     200     500 400
Single reporting segment                
Operating expenses:                
Net (loss) income (4,690)     (4,758)     (32,837) 9,701
Single reporting segment | Operating segment                
Operating expenses:                
General and administrative expense 1,561     1,334     4,890 4,785
Research and development 4,298     2,329     10,652 4,460
Clinical expenses             (25,000) (24,985)
Legal settlement loss             16,587  
Stock-based compensation expense 444     340     807 1,013
Total operating expenses 6,303     4,003     32,936 (14,727)
Operating (loss) gain (6,303)     (4,003)     (32,936) 14,727
Interest income 15     173     166 441
Interest on convertible notes (614)     (1,143)     (1,934) (3,469)
Amortization of discount on convertible notes       (110)       (348)
Standby equity purchase agreement commitment fee             (325)  
Issuance costs for private placement of shares and warrants through placement agent (Note 5) (1,628)           (1,628)  
Legal settlement revaluation 3,842           3,842  
Loss on induced conversion               (1,180)
Finance charges (2)     (2)     (22) (25)
Gain on restructuring of payables       327       407
Loss on derivatives               (852)
Net (loss) income $ (4,690)     $ (4,758)     $ (32,837) $ 9,701